Medication info

Rinatri Duo Tablets 2.5/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Bionex Co., Ltd.
Appearance
Light pink oval film-coated tablet
Packaging
60 tablets/box [(10 tablets/PTP×6)]
Approval status
Active

MFDS item code 202001309 · Approved 2020.02.24

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. Dose increases should be made gradually to reduce gastrointestinal adverse reactions associated with metformin use. 1. Patients not currently receiving metformin: For patients with no history of previous antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients with inadequate glycemic control on metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient's previous metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from concomitant therapy with linagliptin and metformin: Patients switching from concomitant therapy with linagliptin and metformin to this medicine should start at their previous doses of linagliptin and metformin. 4. Patients with inadequate glycemic control on concomitant therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's previous metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). 5. Patients with inadequate glycemic control on concomitant therapy with insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's previous metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not Administer to the Following Patients).

Ingredients

Manufacturer
Bionex Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty in blood sugar control
View approved original text

This drug is used to help control blood sugar in adult patients with type 2 diabetes. It is especially effective for patients who have not previously been treated with diabetes medications or who find it difficult to control blood sugar with monotherapy. This drug can also be used when metformin monotherapy is insufficient, and it is administered when switching from linagliptin and metformin combination therapy. If blood glucose control is inadequate with metformin and sulfonylurea combination therapy, insulin and metformin combination therapy, or metformin and empagliflozin combination therapy, this drug can be added to enhance therapeutic effectiveness. In summary, this drug is used to improve blood glucose control in various therapeutic situations.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. Dose increases should be made gradually to reduce gastrointestinal adverse reactions associated with metformin use. 1. Patients not currently receiving metformin: For patients with no history of previous antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients with inadequate glycemic control on metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient's previous metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from concomitant therapy with linagliptin and metformin: Patients switching from concomitant therapy with linagliptin and metformin to this medicine should start at their previous doses of linagliptin and metformin. 4. Patients with inadequate glycemic control on concomitant therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's previous metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). 5. Patients with inadequate glycemic control on concomitant therapy with insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's previous metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not Administer to the Following Patients).

Precautions

This drug is used in the treatment of diabetes, with two main ingredients working together to control blood sugar. Before taking this drug, it should not be used if there are specific diseases or allergies. For example, it should be avoided in cases of severe renal impairment, liver dysfunction, type 1 diabetes, acute cardiac issues, severe infections, pregnancy, or breastfeeding. This drug can cause a rare but serious side effect known as lactic acidosis, so if symptoms such as muscle pain, abdominal pain, weakness, or difficulty breathing occur during use, a doctor should be notified immediately. Hypoglycemic reactions can occur if blood sugar falls too low. Caution is particularly needed when used with insulin or other hypoglycemic agents, and immediate action should be taken if symptoms arise. Regular blood tests are required to monitor kidney function due to the risk of impaired renal function, and the use of this drug may be temporarily stopped in situations where kidney function deteriorates rapidly. Some patients may experience side effects such as pancreatitis or bullous pemphigoid, so if severe abdominal pain or skin abnormalities develop during treatment, a doctor should be consulted immediately. This drug can lower vitamin B12 levels, so it is important to check for vitamin B12 deficiency during long-term use. Furthermore, this drug may interact with other medications, so if any other drugs are currently being taken, it is essential to inform a doctor or pharmacist, especially if those medications may affect kidney function. Women who are pregnant or planning to become pregnant are advised to consider insulin therapy instead of this drug, and it is best not to use this drug while breastfeeding. This drug is not recommended for use in children under 10 years of age, as safety and efficacy have not been established. Elderly patients may require dosage adjustments and regular monitoring due to the potential for decreased kidney function. There are no specific reported effects on driving or operating machinery, but caution is needed due to the possibility of hypoglycemia and related symptoms. In case of overdose, gastrointestinal disturbances and the risk of lactic acidosis may occur, and immediate treatment at a hospital is required, with blood dialysis being the most effective detoxification method. This drug should be stored in a tightly closed container, away from moisture and out of reach of children, and should not be transferred to another container.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • hypoglycemia
  • taste disturbance
  • cough
  • loss of appetite
Show 138 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • mucosal ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • bullous pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • loss of appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorders
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • anxiety
  • mood disorders
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • laceration
  • palpitations
  • dry eye
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • hypotension
  • flushing
  • hepatic steatosis
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • thyroid enlargement
  • anemia
  • dizziness
  • sensory loss
  • pruritus
  • hypertension
  • benign prostatic hyperplasia
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • diarrhea
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • anal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • stomatitis
  • increased glycosylated hemoglobin
  • increased blood glucose
  • increased blood creatinine
  • facial swelling
  • hyperthermia
  • back pain
  • osteoarthritis
  • limb pain
  • rotator cuff syndrome
  • headache
  • subdural effusion
  • damage
  • toxicity and procedural complications
  • corneal abrasion
  • falls
  • upper limb fracture
  • voice disorder
  • epistaxis
  • confusional state
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly closed container away from air and moisture, and the temperature should be maintained between 1 to 30 degrees Celsius at room temperature. This storage method will help maintain the drug's effectiveness and prevent deterioration.

Appearance and packaging

Appearance

Light pink oval film-coated tablet

Package unit

60 tablets/box [(10 tablets/PTP×6)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.